During the year, the number of multi-billion-dollar sales transactions continued to rise, with some companies participating more than once.Analysts even suggested that there might be more significant M&A deals by 2025.Currently, the following are the largest M&A deals of 2024:

Johnson & Johnson Acquires IVL Leader Shockwave Medical for $13.1 Billion

In May, Johnson & Johnson Medical TechnologiesCompleted the Most Expensive Medtech Acquisition of 2024, it acquired Shockwave Medical.Under the agreement, J&J acquired all outstanding shares of Shockwave for $335 per share in cash. Shockwave Medical now operates as a business unit of J&J MedTech.

Shockwave Medical's IVL Technology Uses Acoustic Pressure Waves to Treat Patients with Calcified Arterial Plaques. This catheter-based treatment helps restore blood flow by cracking calcium lesions. Its applications include coronary artery disease (CAD) and peripheral artery disease (PAD), often used in conjunction with stent placement. Shockwave also achieves this throughAcquisition of Neovasc One Year AgoProvide treatment for refractory angina.

Edwards Sells Its Critical Care Business to BD for $4.2 Billion

Edwards Lifesciences Announced at the end of last year, it plans to spin off its critical care business. However, BD announced in June that itCompleted an all-cash transaction to acquire the patient monitoring business unit.。

The two companies said in September that they had completed the transaction.BD Acquires Business Unit for $4.2 Billion。

Critical Care to Operate as Independent Business Unit Within BD Medical in Irvine. Katie Szyman, Vice President of Edwards Critical Care, to Continue Leading the Division. Edwards stated in a press release that it plans to use the net proceeds to fund strategic initiatives, including previously announced acquisitions and stock repurchases.

Baxter Finds Private Equity Buyer for Its Renal Care Business – $3.8 Billion

January 2023,Baxter Announces Plan to Spin Off Its Renal Care and Acute Therapies UnitsAs an independent publicly traded company. At the time, it indicated that the company was expected to remain independent for the next 12 to 18 months. In July of last year,Baxter Chooses "Vantive" as the Proposed Business Name。

After approximately 20 months of searching for a buyer, the company reached an agreement with the private equity firm Carlyle Group,Sold the division for $3.8 billion in AugustBaxter plans to use the proceeds to reduce debt within its established capital allocation priorities.

Over the past decade or so, Carlyle has invested over $40 billion in enterprise value in the medical technology sector. It was reported last year that it was in talks with Medtronic toAcquisition of the Patient Monitoring and Respiratory Interventions Business of This Medical Technology GiantIn 2014, the group won a bidding war for $4 billion.Price Acquires Johnson & Johnson's Orthopedic Clinical DiagnosisBlood testing business. Last year, it eventually sold the business to Quidel for $6 billion. Carlyle alsoContributed to the $34 billion investment in Medline in 2021. Carlyle is an investor in One Medical, the companySold to Amazon for nearly $4 billion last year。

Boston Scientific Finalizes Acquisition of Axonics for $3.7 Billion

Boston ScientificThe company first announced its plan to acquire Axonics in January., but due to the FTCRequest for more information about this acquisition, the completion of the transaction has been postponed.

Two CompaniesCompleted the acquisition in November, Expanding Boston Scientific's urology portfolio by adding Axonics' Sacral Neuromodulation (SNM) system.

Axonics is known for its neuromodulation systems, including the fourth-generation R20 rechargeable SNM and the non-rechargeable F15 SNM systems. Both treat urinary and bowel dysfunction by delivering mild electrical pulses to the sacral nerves. The company also offers Bulkamid, a urethral bulking agent for the treatment of stress urinary incontinence.

Earlier this year, BTIG analysts Marie Thibault and Sam EiberView the Acquisition of Axonics as a Strategic Fit, and pointed out that the penetration rate of the sacral nerve modulation market is significantly insufficient. Medtronic currently dominates this field, with Axonics holding a 27% market share.

J&J Engages in Another Acquisition with V-Wave — $1.7 Billion

Johnson & Johnson Medical Technologies did not wait long before carrying out its second major acquisition of 2024, announcing the acquisition of V-Wave in August, and thenCompleted a $1.7 billion acquisition in OctoberJ&J's relationship with V-Wave can also be traced back to the initial investment in the company in 2016.

V-Wave Develops Cardiovascular Implant Technology Specifically for Heart Failure with Reduced Ejection Fraction (HFrEF). The Company's Ventura Atrial Shunt Was Introduced in 2019.Received FDA Breakthrough Device Designation for the first time in [Year]`, and on`CE Mark Obtained in 2020。

Ventura is placed in the heart through minimally invasive, catheter-based surgery, filling the therapeutic gap between guideline-directed medical therapy as a first-line treatment and highly invasive heart replacement therapies, including left ventricular assist devices (LVAD) and heart transplantation.

Owens & Minor Acquires Medical Device Supplier for $1.4 Billion

In July, Owens & MinorAgree to pay 1.4 billion US dollarsAcquisition of Rotech Healthcare, a privately held home care business.

This Orlando, Florida-based company provides home medical equipment in the United States. It has more than 4,200 employees and offers products and services across 46 states through approximately 325 operating locations. According to Owens & Minor, Rotech generated approximately $750 million in revenue in 2023.

This acquisition strengthens Owens & Minor's Patient Direct product offerings by expanding a wide range of product portfolios, including respiratory, sleep apnea, diabetes, and wound care. It also provides an opportunity to enter the durable medical equipment market.

Boston Scientific Acquires Stroke Prevention Technology Manufacturer Silk Road Medical for $1.18 Billion

September, Boston ScientificThe company completed the acquisition of Silk Road Medical, headquartered in Sunnyvale, California, for $1.18 billion.However, like the deal with Axonics, it is not without obstacles.

In August, Boston ScientificThe company voluntarily withdrew its pre-merger notification and report form.. This is to give the U.S. Federal Trade Commission (FTC) more time to review the proposed acquisition. However,The eventual expiration of antitrust measures allowed these companies toComplete the acquisition within 5 days, thereby proceeding with the acquisition.

Silk Road Medical develops products aimed at preventing strokes in patients with carotid artery disease. The technology is used in a minimally invasive procedure called Transcarotid Artery Revascularization (TCAR).

Zeiss Invests $1 Billion — $1.07 Billion in Ophthalmology

Carl Zeiss Meditec Announced in AprilCompletion of the Acquisition of D.O.R.C. (Dutch Ophthalmic Research Center). The Germany-based company acquired DORC from French investment firm Eurazeo in a deal valued at 985 million euros ($1.07 billion).

It is expected that this acquisition will enhance and complement its extensive ophthalmology portfolio and a series of digitally connected workflow solutions. The company develops products that address eye conditions such as retinal diseases, cataracts, glaucoma, and refractive errors.

According to Zeiss, D.O.R.C., as a leader in the retinal surgery equipment and consumables market, has made significant contributions. The company expects that D.O.R.C.'s Eva Nexus platform, combined with its range of visualization, diagnostic, and therapeutic devices as well as surgical instruments and consumables—all connected to a digital ecosystem—will enable the creation of efficient clinical workflows.